Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary
I'm PortAI, I can summarize articles.
Niagen Bioscience IncQ) reported adjusted earnings of 6 cents per share for the quarter ended March 31, surpassing last year's EPS of -1 cent and analysts' expectations of 2 cents. Revenue increased by 37.6% to $30.48 million, exceeding the forecast of $27.10 million. The company achieved a net income of $5.06 million. Niagen's shares rose 26.5% this quarter and 64.6% year-to-date. Analysts maintain a "buy" rating, with a median 12-month price target of $8.05.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments